Should Viz.ai prioritize expanding its stroke detection algorithms to cover more rare conditions, potentially increasing false positives, or focus on improving accuracy for common stroke types?

Introduction

The trade-off Viz.ai faces is whether to expand its stroke detection algorithms to cover more rare conditions, potentially increasing false positives, or focus on improving accuracy for common stroke types. This decision involves balancing the breadth of detection capabilities against the precision of existing algorithms. I'll analyze this trade-off by examining the product context, potential impacts, key metrics, and experimental approaches to guide our decision-making process.

Step 1

Clarifying Questions (3 minutes)

• Based on Viz.ai's current market position, I'm thinking this decision could significantly impact our competitive advantage. Could you provide more context on our current market share and the competitive landscape?

Why it matters: Helps assess the urgency and potential impact of expanding vs. improving existing algorithms. Expected answer: Viz.ai has a strong market position but faces increasing competition. Impact on approach: Would influence whether to prioritize differentiation through rare condition detection or solidify leadership in common stroke detection.

• Considering our revenue model, I assume accuracy is crucial for maintaining customer trust and renewals. How does our current pricing structure relate to the breadth vs. accuracy of our detection capabilities?

Why it matters: Informs the potential financial implications of increased false positives or improved accuracy. Expected answer: Pricing is tied to both accuracy and range of detectable conditions. Impact on approach: Would help balance the trade-off between expanding capabilities and maintaining high accuracy.

• From a user perspective, I'm curious about the current false positive rate and its impact on clinician workflow. Can you share any data on how false positives affect user satisfaction and trust in the system?

Why it matters: Helps quantify the potential downside of expanding to rare conditions. Expected answer: False positives create additional work for clinicians but are currently at an acceptable level. Impact on approach: Would influence the acceptable threshold for increased false positives when expanding to rare conditions.

• Regarding technical feasibility, I'm wondering about the current state of our AI models. How much additional training data and computational resources would be required to expand to rare conditions versus improving accuracy for common types?

Why it matters: Assesses the technical investment required for each option. Expected answer: Expanding to rare conditions requires significant new data collection and model retraining. Impact on approach: Would help determine if the technical investment aligns with potential benefits of expansion.

• Considering our development timeline, how urgent is the need to make this decision? Are there any upcoming product releases or market events that could influence our choice?

Why it matters: Helps prioritize the decision within our overall product roadmap. Expected answer: Decision needed within the next quarter to align with annual product planning. Impact on approach: Would influence the depth of analysis and experimentation we can conduct before making a decision.